These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 17538553

  • 21. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ.
    N Engl J Med; 2004 Oct 21; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract] [Full Text] [Related]

  • 22. Policy developments in regulatory approval.
    Temple R.
    Stat Med; 2002 Oct 15; 21(19):2939-48. PubMed ID: 12325110
    [Abstract] [Full Text] [Related]

  • 23. Sure cure: public policy on drug efficacy before 1962.
    Swann JP.
    Publ Am Inst Hist Pharm; 1997 Oct 15; 16():223-61. PubMed ID: 11619897
    [No Abstract] [Full Text] [Related]

  • 24. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP.
    Food Drug Law J; 2008 Oct 15; 63(3):623-45. PubMed ID: 19031663
    [No Abstract] [Full Text] [Related]

  • 25. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM, Temple R, Throckmorton DC, Lesko LJ.
    Clin Pharmacol Ther; 2007 Feb 15; 81(2):298-304. PubMed ID: 17259955
    [Abstract] [Full Text] [Related]

  • 26. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan 15; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 27. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
    Falit BP.
    Seton Hall Law Rev; 2007 Jan 15; 37(4):969-1049. PubMed ID: 18363220
    [No Abstract] [Full Text] [Related]

  • 28. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT.
    Cornell Law Rev; 2008 Jul 15; 93(5):939-80. PubMed ID: 18618965
    [No Abstract] [Full Text] [Related]

  • 29. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
    Viscusi WK, Rowland SR, Dorfman HL, Walsh CJ.
    Spec Law Dig Health Care Law; 1996 Mar 15; (205):9-52. PubMed ID: 10156421
    [No Abstract] [Full Text] [Related]

  • 30. Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.
    Segreti AC, Leung HM, Koch GG, Davis RL, Mohberg NR, Peace KE.
    J Biopharm Stat; 2001 Nov 15; 11(4):347-72. PubMed ID: 12018784
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Changing requirements for evaluation of pharmacologic agents.
    Chesney RW, Christensen ML.
    Pediatrics; 2004 Apr 15; 113(4 Suppl):1128-32. PubMed ID: 15060209
    [Abstract] [Full Text] [Related]

  • 33. Disease models.
    Gobburu J.
    Clin Adv Hematol Oncol; 2008 Apr 15; 6(4):241-2. PubMed ID: 18496490
    [No Abstract] [Full Text] [Related]

  • 34. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM.
    Regul Toxicol Pharmacol; 2009 Nov 15; 55(2):181-7. PubMed ID: 19589365
    [Abstract] [Full Text] [Related]

  • 35. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C.
    Pharmacoepidemiol Drug Saf; 2002 Sep 15; 11(6):439-46. PubMed ID: 12426927
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B.
    Nat Biotechnol; 2006 May 15; 24(5):478. PubMed ID: 16680113
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C.
    Food Drug Law J; 2006 May 15; 61(2):295-383. PubMed ID: 16903034
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.